Photo with 56 notes
An international collaboration between the University of Helsinki and École Polytechnique Fédérale de Lausanne reported today in the high-profile journal, Embo Molecular Medicine, that vitamin B3 form, nicotinamide riboside, can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Mitochondrial myopathy is the most frequent form of adult mitochondrial disorder. The typical symptoms in the patients are muscle weakness, pain and cramps. Despite the progressive nature of these diseases, no curative treatment is available.
In their current publication, Dr Nahid Khan in Prof Anu Suomalainen-Wartiovaara’s group showed that feeding mice with food supplemented with B3 form, nicotinamide riboside, delayed their mitochondrial myopathy. The treatment increased mitochondrial mass and function, and cured the structural abnormalities.
Three compounds contain the nicotinamide ring and are used to produce NAD+ via the salvage pathway: nicotinic acid, nicotinamide, and nicotinamide riboside.